Immunogenicity, efficacy and safety of Nuwiq® (human‐cl rhFVIII) in previously untreated patients with severe haemophilia A—Interim results from the NuProtect Study

Introduction Nuwiq® (Human‐cl rhFVIII) is a fourth generation recombinant FVIII, produced in a human cell line, without chemical modification or protein fusion. No inhibitors developed in studies with Nuwiq® in 201 previously treated patients with haemophilia A (HA). The immunogenicity, efficacy and...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Haemophilia : the official journal of the World Federation of Hemophilia 2018-03, Vol.24 (2), p.211-220
Hauptverfasser:	Liesner, R. J., Abashidze, M., Aleinikova, O., Altisent, C., Belletrutti, M. J., Borel‐Derlon, A., Carcao, M., Chambost, H., Chan, A. K. C., Dubey, L., Ducore, J., Fouzia, N. A., Gattens, M., Gruel, Y., Guillet, B., Kavardakova, N., El Khorassani, M., Klukowska, A., Lambert, T., Lohade, S., Sigaud, M., Turea, V., Wu, J. K. M., Vdovin, V., Pavlova, A., Jansen, M., Belyanskaya, L., Walter, O., Knaub, S., Neufeld, E. J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Chemical modification Fusion protein FVIII inhibitors haemophilia A Hemophilia Human‐cl rhFVIII Immunogenicity Nuwiq Patients previously untreated patients Prophylaxis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!